Trial by CCN2: a standardized test for fibroproliferative disease?

Journal of Cell Communication and Signaling

Andrew Leask¹ 

[1] University of Western Ontario$$

关键词: CCN2;   

DOI  :  10.1007/s12079-009-0041-y

学科分类：分子生物学，细胞生物学和基因

来源: Springer

【 摘 要 】

A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relative levels of vascular endothelial growth factor (VEGF) and CCN2 (connective tissue growth factor [CTGF]) were examined in proliferative diabetic retinopathy (PDR). This paper is the subject of this commentary.

【 授权许可】

Unknown